The therapeutic effect of AR on nephrotic syndrome (NS) may be demonstrated by reducing the expressions of arginine vasopressin (AVP) mRNA, AVP V2 receptor mRNA, and AVP-dependent aquaporin-2 (AQP2) mRNA, thereby eliminating edema. The gene discussed is AQP2; the disease is nephrotic syndrome.